InvestSMART

Memphasys Limited (ASX:MEM)

ALERT: Price-sensitive ASX Announcement for MEM
Current share price for MEM : $0.005 -0.002 (-23.08%)+
Announcement
Release
1 Jul 2026 8:48AM
Price at Release
$0.007
Full Release
download
Summary
Memphasys Limited has secured a three-year exclusive commercial distribution agreement with IVF Envimed Co., Ltd. for its Felix™ sperm separation system in Thailand. This agreement, valued at approximately A$430,500, aims to tap into Thailand’s IVF market, which undertakes between 20,000 to 30,000 cycles annually across 110 clinics. The agreement is part of Memphasys' strategy to build a diversified revenue base for Felix™ in South-East Asia, with anticipated Thai FDA regulatory approval within three to six months. Together with a similar agreement in Vietnam, Memphasys’ minimum contracted revenue in the region is expected to reach A$1.0 million, contributing to a total FY2026 revenue of approximately A$3.0 million. The partnership with IVF Envimed, which has extensive experience in the Thai IVF market, will enhance the distribution, clinical support, and adoption of Felix™.
Key Points
  • Exclusive three-year agreement with IVF Envimed for Felix™ in Thailand
  • Total minimum contracted value approximately A$430,500 over three years
  • Thailand conducts 20,000–30,000 IVF cycles annually
  • Thai FDA approval anticipated within approximately three to six months
  • Agreement contributes to A$1.0 million in South-East Asian revenue
  • Total FY2026 Felix™ contracted revenues now approximately A$3.0M
  • IVF Envimed has over 15 years of experience and relationships with all IVF clinics in Thailand
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.